Type i IFN is necessary and sufficient for inflammation-induced red blood cell alloimmunization in mice

Journal of Immunology

Volumn 199, Issue 3, 2017, Pages 1041-1050

  Gibb, David R ^a   Liu, Jingchun ^a   Natarajan, Prabitha ^a   Santhanakrishnan, Manjula ^a   Madrid, David J ^a   Eisenbarth, Stephanie C ^a   Zimring, James C ^b,c   Iwasaki, Akiko ^a,d   Hendrickson, Jeanne E ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Bloodworks Northwest Research Institute   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; BETA INTERFERON RECEPTOR; INTERFERON; ALLOANTIBODY; ALPHA BETA INTERFERON RECEPTOR; ANTIGEN; IPS-1 PROTEIN, MOUSE; POLYINOSINIC POLYCYTIDYLIC ACID; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ALLOIMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ERYTHROCYTE TRANSFUSION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ADVERSE EFFECTS; ANIMAL; ERYTHROCYTE; IMMUNOLOGY; INFLAMMATION; METABOLISM; TRANSGENIC MOUSE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIGENS; AUTOIMMUNITY; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; HUMANS; INFLAMMATION; INTERFERON TYPE I; ISOANTIBODIES; MICE; MICE, TRANSGENIC; POLY I-C; RECEPTOR, INTERFERON ALPHA-BETA; SIGNAL TRANSDUCTION;

EID: 85026218383     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1700401     Document Type: Article

References (68)

1. Blumberg, N., K. Peck, K. Ross, and E. Avila. 1983. Immune response to chronic red blood cell transfusion. Vox Sang. 44: 212-217
2. Fluit, C. R., V. A. Kunst, and A. M. Drenthe-Schonk. 1990. Incidence of red cell antibodies after multiple blood transfusion. Transfusion 30: 532-535
3. Heddle, N. M., R. L. Soutar, P. L. O'Hoski, J. Singer, J. A. McBride, M. A. Ali, and J. G. Kelton. 1995. A prospective study to determine the frequency and clinical significance of alloimmunization post-transfusion. Br. J. Haematol. 91: 1000-1005
4. Hoeltge, G. A., R. E. Domen, L. A. Rybicki, and P. A. Schaffer. 1995. Multiple red cell transfusions and alloimmunization. Experience with 6996 antibodies detected in a total of 159, 262 patients from 1985 to 1993. Arch. Pathol. Lab. Med. 119: 42-45
5. Redman, M., F. Regan, and M. Contreras. 1996. A prospective study of the incidence of red cell allo-immunisation following transfusion. Vox Sang. 71: 216-220
6. Vichinsky, E. P., A. Earles, R. A. Johnson, M. S. Hoag, A. Williams, and B. Lubin. 1990. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N. Engl. J. Med. 322: 1617-1621
7. Yazdanbakhsh, K., R. E. Ware, and F. Noizat-Pirenne. 2012. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood 120: 528-537
8. (FDA), U. D. O. H. A. H. S. 2014. Fatalities reported to the FDA following blood collection and transfusion: annual summary for fiscal year 2014. Available at: http://www.fda.gov/downloads/biologicsbloodvaccines/safetyavailability/reportaproblem/transfusiondonationfatalities/ucm459461.pdf. Accessed: November 11, 2015
9. Körmöczi, G. F., and W. R. Mayr. 2014. Responder individuality in red blood cell alloimmunization. Transfus. Med. Hemother. 41: 446-451
10. Nickel, R. S., J. E. Hendrickson, R. M. Fasano, E. K. Meyer, A. M. Winkler, M. M. Yee, P. A. Lane, Y. A. Jones, F. D. Pashankar, T. New, et al. 2016. Impact of red blood cell alloimmunization on sickle cell disease mortality: a case series. Transfusion 56: 107-114
11. Telen, M. J., A. Afenyi-Annan, M. E. Garrett, M. R. Combs, E. P. Orringer, and A. E. Ashley-Koch. 2015. Alloimmunization in sickle cell disease: changing antibody specificities and association with chronic pain and decreased survival. Transfusion 55: 1378-1387
12. Fasano, R. M., G. S. Booth, M. Miles, L. Du, T. Koyama, E. R. Meier, and N. L. Luban. 2015. Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease. Br. J. Haematol. 168: 291-300
13. Papay, P., K. Hackner, H. Vogelsang, G. Novacek, C. Primas, W. Reinisch, A. Eser, A. Mikulits, W. R. Mayr, and G. F. Kormoczi. 2012. High risk of transfusion-induced alloimmunization of patients with inflammatory bowel disease. Am J Med. 125: 717.e1-8
14. Yazer, M. H., D. J. Triulzi, B. Shaz, T. Kraus, and J. C. Zimring. 2009. Does a febrile reaction to platelets predispose recipients to red blood cell alloimmunization? Transfusion 49: 1070-1075
15. Ramsey, G., and S. J. Smietana. 1995. Multiple or uncommon red cell alloantibodies in women: association with autoimmune disease. Transfusion 35: 582-586
16. Evers, D., J. G. van der Bom, J. Tijmensen, R. A. Middelburg, M. de Haas, S. Zalpuri, K. M. de Vooght, D. van de Kerkhof, O. Visser, N. C. Péquériaux, et al. 2016. Red cell alloimmunisation in patients with different types of infections. Br. J. Haematol. 175: 956-966
17. Arneja, A., J. E. Salazar, W. Jiang, J. E. Hendrickson, J. C. Zimring, and C. J. Luckey. 2016. Interleukin-6 receptor-alpha signaling drives anti-RBC alloantibody production and T-follicular helper cell differentiation in a murine model of red blood cell alloimmunization. Haematologica 101: e440-e444
18. Gibb, D. R., S. Calabro, D. Liu, C. A. Tormey, S. L. Spitalnik, J. C. Zimring, J. E. Hendrickson, E. A. Hod, and S. C. Eisenbarth. 2016. The Nlrp3 inflammasome does not regulate alloimmunization to transfused red blood cells in mice. EBioMedicine 9: 77-86
19. Elayeb, R., M. Tamagne, P. Bierling, F. Noizat-Pirenne, and B. Vingert. 2016. Red blood cell alloimmunization is influenced by the delay between Toll-like receptor agonist injection and transfusion. Haematologica 101: 209-218
20. Hendrickson, J. E., M. Desmarets, S. S. Deshpande, T. E. Chadwick, C. D. Hillyer, J. D. Roback, and J. C. Zimring. 2006. Recipient inflammation affects the frequency and magnitude of immunization to transfused red blood cells. Transfusion 46: 1526-1536
21. Yu, J., S. Heck, and K. Yazdanbakhsh. 2007. Prevention of red cell alloimmunization by CD25 regulatory T cells in mouse models. Am. J. Hematol. 82: 691-696
22. Ryder, A. B., J. C. Zimring, and J. E. Hendrickson. 2014. Factors influencing RBC alloimmunization: lessons learned from murine models. Transfus. Med. Hemother. 41: 406-419
23. Bao, W., J. Yu, S. Heck, and K. Yazdanbakhsh. 2009. Regulatory T-cell status in red cell alloimmunized responder and nonresponder mice. Blood 113: 5624-5627
24. Stowell, S. R., K. R. Girard-Pierce, N. H. Smith, K. L. Henry, C. M. Arthur, J. C. Zimring, and J. E. Hendrickson. 2014. Transfusion of murine red blood cells expressing the human KEL glycoprotein induces clinically significant alloantibodies. Transfusion 54: 179-189
25. Hendrickson, J. E., E. A. Hod, S. L. Spitalnik, C. D. Hillyer, and J. C. Zimring. 2010. Storage of murine red blood cells enhances alloantibody responses to an erythroid-specific model antigen. Transfusion 50: 642-648
26. Yoneyama, M., M. Kikuchi, T. Natsukawa, N. Shinobu, T. Imaizumi, M. Miyagishi, K. Taira, S. Akira, and T. Fujita. 2004. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5: 730-737
27. Gitlin, L., W. Barchet, S. Gilfillan, M. Cella, B. Beutler, R. A. Flavell, M. S. Diamond, and M. Colonna. 2006. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc. Natl. Acad. Sci. USA 103: 8459-8464
28. Alexopoulou, L., A. C. Holt, R. Medzhitov, and R. A. Flavell. 2001. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413: 732-738
29. Salem, M. L., S. A. El-Naggar, A. Kadima, W. E. Gillanders, and D. J. Cole. 2006. The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. Vaccine 24: 5119-5132
30. Meylan, E., and J. Tschopp. 2006. Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. Mol. Cell 22: 561-569
31. McNab, F., K. Mayer-Barber, A. Sher, A. Wack, and A. O'Garra. 2015. Type I interferons in infectious disease. Nat. Rev. Immunol. 15: 87-103
32. Proietti, E., L. Bracci, S. Puzelli, T. Di Pucchio, P. Sestili, E. De Vincenzi, M. Venditti, I. Capone, I. Seif, E. De Maeyer, et al. 2002. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J. Immunol. 169: 375-383
33. Le Bon, A., C. Thompson, E. Kamphuis, V. Durand, C. Rossmann, U. Kalinke, and D. F. Tough. 2006. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J. Immunol. 176: 2074-2078
34. Olsen, N., T. Sokka, C. L. Seehorn, B. Kraft, K. Maas, J. Moore, and T. M. Aune. 2004. A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells. Ann. Rheum. Dis. 63: 1387-1392
35. Higgs, B. W., Z. Liu, B. White, W. Zhu, W. I. White, C. Morehouse, P. Brohawn, P. A. Kiener, L. Richman, D. Fiorentino, et al. 2011. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann. Rheum. Dis. 70: 2029-2036
36. Båve, U., G. Nordmark, T. Lövgren, J. Rönnelid, S. Cajander, M. L. Eloranta, G. V. Alm, and L. Rönnblom. 2005. Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum. 52: 1185-1195
37. Baechler, E. C., J. W. Bauer, C. A. Slattery, W. A. Ortmann, K. J. Espe, J. Novitzke, S. R. Ytterberg, P. K. Gregersen, T. W. Behrens, and A. M. Reed. 2007. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol. Med. 13: 59-68
38. Assassi, S., M. D. Mayes, F. C. Arnett, P. Gourh, S. K. Agarwal, T. A. McNearney, D. Chaussabel, N. Oommen, M. Fischbach, K. R. Shah, et al. 2010. Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum. 62: 589-598
39. Ytterberg, S. R., and T. J. Schnitzer. 1982. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum. 25: 401-406
40. Feng, X., H. Wu, J. M. Grossman, P. Hanvivadhanakul, J. D. FitzGerald, G. S. Park, X. Dong, W. Chen, M. H. Kim, H. H. Weng, et al. 2006. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 54: 2951-2962
41. Crow, M. K., K. A. Kirou, and J. Wohlgemuth. 2003. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 36: 481-490
42. Baechler, E. C., F. M. Batliwalla, G. Karypis, P. M. Gaffney, W. A. Ortmann, K. J. Espe, K. B. Shark, W. J. Grande, K. M. Hughes, V. Kapur, et al. 2003. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA 100: 2610-2615
43. Bronson, P. G., C. Chaivorapol, W. Ortmann, T. W. Behrens, and R. R. Graham. 2012. The genetics of type I interferon in systemic lupus erythematosus. Curr. Opin. Immunol. 24: 530-537
44. Yao, Y., L. Richman, B. W. Higgs, C. A. Morehouse, M. de los Reyes, P. Brohawn, J. Zhang, B. White, A. J. Coyle, P. A. Kiener, and B. Jallal. 2009. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 60: 1785-1796
45. Petri, M., D. J. Wallace, A. Spindler, V. Chindalore, K. Kalunian, E. Mysler, C. M. Neuwelt, G. Robbie, W. I. White, B. W. Higgs, et al. 2013. Sifalimumab, a human anti-interferon-a monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum. 65: 1011-1021
46. Stack, G., and C. A. Tormey. 2016. Estimating the immunogenicity of blood group antigens: a modified calculation that corrects for transfusion exposures. Br. J. Haematol. 175: 154-160
47. Noizat-Pirenne, F., C. Tournamille, P. Bierling, F. Roudot-Thoraval, P. Y. Le Pennec, P. Rouger, and H. Ansart-Pirenne. 2006. Relative immunogenicity of Fya and K antigens in a Caucasian population, based on HLA class II restriction analysis. Transfusion 46: 1328-1333
48. Marsh, W. L., and C. M. Redman. 1990. The kell blood group system: a review. Transfusion 30: 158-167
49. Müller, U., U. Steinhoff, L. F. Reis, S. Hemmi, J. Pavlovic, R. M. Zinkernagel, and M. Aguet. 1994. Functional role of type I and type II interferons in antiviral defense. Science 264: 1918-1921
50. Sun, Q., L. Sun, H. H. Liu, X. Chen, R. B. Seth, J. Forman, and Z. J. Chen. 2006. The specific and essential role of MAVS in antiviral innate immune responses. Immunity 24: 633-642
51. Sato, M., H. Suemori, N. Hata, M. Asagiri, K. Ogasawara, K. Nakao, T. Nakaya, M. Katsuki, S. Noguchi, N. Tanaka, and T. Taniguchi. 2000. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction. Immunity 13: 539-548
52. Honda, K., H. Yanai, H. Negishi, M. Asagiri, M. Sato, T. Mizutani, N. Shimada, Y. Ohba, A. Takaoka, N. Yoshida, and T. Taniguchi. 2005. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434: 772-777
53. Yamamoto, M., S. Sato, H. Hemmi, K. Hoshino, T. Kaisho, H. Sanjo, O. Takeuchi, M. Sugiyama, M. Okabe, K. Takeda, and S. Akira. 2003. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301: 640-643
54. Adachi, O., T. Kawai, K. Takeda, M. Matsumoto, H. Tsutsui, M. Sakagami, K. Nakanishi, and S. Akira. 1998. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9: 143-150
55. Smith, N. H., K. L. Henry, C. M. Cadwell, A. Bennett, J. E. Hendrickson, T. Frame, and J. C. Zimring. 2012. Generation of transgenic mice with antithetical KEL1 and KEL2 human blood group antigens on red blood cells. Transfusion 52: 2620-2630
56. Desmarets, M., C. M. Cadwell, K. R. Peterson, R. Neades, and J. C. Zimring. 2009. Minor histocompatibility antigens on transfused leukoreduced units of red blood cells induce bone marrow transplant rejection in a mouse model. Blood 114: 2315-2322
57. Peterson, K. R., H. Fedosyuk, L. Zelenchuk, B. Nakamoto, E. Yannaki, G. Stamatoyannopoulos, S. Ciciotte, L. L. Peters, L. M. Scott, and T. Papayannopoulou. 2004. Transgenic Cre expression mice for generation of erythroid-specific gene alterations. Genesis 39: 1-9
58. Stowell, S. R., K. L. Henry, N. H. Smith, K. E. Hudson, G. R. Halverson, J. C. Park, A. M. Bennett, K. R. Girard-Pierce, C. M. Arthur, S. T. Bunting, et al. 2013. Alloantibodies to a paternally derived RBC KEL antigen lead to hemolytic disease of the fetus/newborn in a murine model. Blood 122: 1494-1504
59. Lund, J., A. Sato, S. Akira, R. Medzhitov, and A. Iwasaki. 2003. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J. Exp. Med. 198: 513-520
60. Longhi, M. P., C. Trumpfheller, J. Idoyaga, M. Caskey, I. Matos, C. Kluger, A. M. Salazar, M. Colonna, and R. M. Steinman. 2009. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J. Exp. Med. 206: 1589-1602
61. Montoya, M., G. Schiavoni, F. Mattei, I. Gresser, F. Belardelli, P. Borrow, and D. F. Tough. 2002. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 99: 3263-3271
62. Ohyagi, H., N. Onai, T. Sato, S. Yotsumoto, J. Liu, H. Akiba, H. Yagita, K. Atarashi, K. Honda, A. Roers, et al. 2013. Monocyte-derived dendritic cells perform hemophagocytosis to fine-tune excessive immune responses. Immunity 39: 584-598
63. Calabro, S., A. Gallman, U. Gowthaman, D. Liu, P. Chen, J. Liu, J. K. Krishnaswamy, M. S. Nascimento, L. Xu, S. R. Patel, et al. 2016. Bridging channel dendritic cells induce immunity to transfused red blood cells. J. Exp. Med. 213: 887-896
64. Gilson, C. R., and J. C. Zimring. 2012. Alloimmunization to transfused platelets requires priming of CD4+ T cells in the splenic microenvironment in a murine model. Transfusion 52: 849-859
65. Scheu, S., P. Dresing, and R. M. Locksley. 2008. Visualization of IFNbeta production by plasmacytoid versus conventional dendritic cells under specific stimulation conditions in vivo. Proc. Natl. Acad. Sci. USA 105: 20416-20421
66. Patil, A., Y. Kumagai, K. C. Liang, Y. Suzuki, and K. Nakai. 2013. Linking transcriptional changes over time in stimulated dendritic cells to identify gene networks activated during the innate immune response. PLoS Comput. Biol. 9: e1003323
67. Edwards, A. D., S. S. Diebold, E. M. Slack, H. Tomizawa, H. Hemmi, T. Kaisho, S. Akira, and C. Reis e Sousa. 2003. Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines. Eur. J. Immunol. 33: 827-833
68. Smith, N. H., E. A. Hod, S. L. Spitalnik, J. C. Zimring, and J. E. Hendrickson. 2012. Transfusion in the absence of inflammation induces antigen-specific tolerance to murine RBCs. Blood 119: 1566-1569